7746-29-4

Usage

Uses

Used in Pharmaceutical Industry:
6-Methoxy-3-methyl-1H-indazole is used as a key intermediate in the synthesis of various pharmaceuticals for its potential antiviral and anti-inflammatory properties. Its unique structure allows for the development of new drugs that can target specific biological pathways, offering potential therapeutic benefits in treating viral infections and inflammatory conditions.
Used in Organic Synthesis:
6-Methoxy-3-methyl-1H-indazole is used as a building block in the synthesis of other organic compounds, particularly in the development of bioactive molecules. Its presence in the molecular structure can impart specific properties to the final product, making it a valuable component in the creation of novel compounds with potential applications in various fields.
Used in Chemical Research:
6-Methoxy-3-methyl-1H-indazole is utilized in chemical research to explore its reactivity, stability, and potential interactions with other molecules. This research can provide valuable insights into the compound's properties and help in the development of new synthetic routes and applications in various industries.

Upstream product

• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 

Downstream Products

• 362512-26-3 6-Benzyloxy-3-methyl-1H-indazole 
• 691900-70-6 tert-butyl-6-methoxy-3-methyl-1-indazole-carboxylate 
• 201286-99-9 3-methyl-1H-indazol-6-ol 
• 518987-37-6 6-methoxy-1H-indazole-3-carbaldehyde 
• 691905-46-1 C₁₆H₁₄N₂O₃ 
• 848468-05-3 C₂₇H₃₈N₂O₅Si 
• 848468-06-4 C₂₇H₃₆N₂O₅Si 
• 201286-96-6 3-methyl-indazole-6-carboxylic acid 

Relevant academic research and scientific papers

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS

The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

6-hydroxy-indazole derivatives for treating glaucoma

Substituted 1-(α-alkyl-ethylamino)-1H-indazol-6-ols useful for lowering and controlling IOP and treating glaucoma are disclosed

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also rela

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate

Indazole derivatives with 5-HT2 receptor activity

A chemical compound of formula (I) wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, monoalkylamino, di

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.